Johnson & Johnson (JNJ-NYSE) reported $1.16 Non-GAAP EPS vs $1.05 estimates; Revenues $15.0 Billion versus $14.45 Billion estimates. Outside of all the items after R&D, acquisitions, and sales, gains, and other items showed a net of $0.88 on GAAP EPS basis, but the street is focusing on the non-GAAP report so far.
This is not an easy quarter to compare year over year because of the large deal it closed, but here are some items: Operational growth was 13.3% (positive currency impact of 2.4%). Domestic sales were up 11.9%, while international sales increased 20.8%, reflecting operational growth of 15.4% and a positive currency impact of 5.4%. On a pro-forma basis, including the net impact of the acquisition of Pfizer Consumer Healthcare in both periods, worldwide sales increased 6.3% operationally. Operational growth was 13.3% (positive currency impact of 2.4%). Domestic sales were up 11.9%, while international sales increased 20.8%, reflecting operational growth of 15.4% (positive currency impact of 5.4%). On a pro-forma basis, including the net impact of the acquisition of Pfizer Consumer Healthcare in both periods, worldwide sales increased 6.3% operationally.
It looks like the formal guidance won’t come out until its conference call. Shares are now up over 2% to $64.50 in pre-market trading as investors are welcoming what they were fearing just two weeks ago.
Jon C. Ogg
April 17, 2007
Jon Ogg can be reached at [email protected]; he does not own securities in the companies he covers.
Top Gaining Stocks
Top Losing Stocks